AM9405
CAS No.
AM9405 ( AM-9405;GAT379;GAT-379 )
Catalog No. M17035 CAS No.
AM9405 (AM-9405, GAT-379) is novel potent, peripherally active cannabinoid type 1 (CB1) and 5-HT3 receptor agonist.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAM9405
-
NoteResearch use only, not for human use.
-
Brief DescriptionAM9405 (AM-9405, GAT-379) is novel potent, peripherally active cannabinoid type 1 (CB1) and 5-HT3 receptor agonist.
-
DescriptionAM9405 (AM-9405, GAT-379) is novel potent, peripherally active cannabinoid type 1 (CB1) and 5-HT3 receptor agonist, inhibits the EFS-induced twitch contraction of the ileum and the colon with IC50 of 0.076 and 45.71 nM, respectively; significantly slows mouse intestinal motility in physiological conditions, reverses hypermotility and reduced pain in mouse models mimicking symptoms of functional GI disorders, such as stress-induced diarrhea and writhing test.
-
SynonymsAM-9405;GAT379;GAT-379
-
PathwayGPCR/G Protein
-
TargetCannabinoid Receptor
-
RecptorCannabinoid Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number--
-
Formula Weight461.44
-
Molecular FormulaC24H33BrN2O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name2-(2,6-dihydroxy-4-(2-methyloctan-2-yl)phenyl)-1,3-dimethyl-1H-benzo[d]imidazol-3-ium bromide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Salaga M, et al. Eur J Pharmacol. 2018 Aug 17;836:34-43.
molnova catalog
related products
-
Alismoxide
Alismoxide has anti-inflammatory effects.
-
Tetrahydromagnolol
Tetrahydromagnolol can activate cannabinoid (CB) receptors.
-
COR659
COR659 is a 2-acylaminothiophene derivative able to suppress alcohol and chocolate self-administration in rats, likely via positive allosteric modulation of the GABAB receptor and antagonism/inverse agonism at the cannabinoid CB1 receptor.